XPO1/CRM1-Selective Inhibitors of Nuclear Export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa)

Giovanni Luca Gravina(University of L'Aquila), Claudio Festuccia(University of L'Aquila), Dilara McCauley(Karyopharm Therapeutics (United States)), Ernesto Di Cesare(University of L'Aquila), Sharon Shacham(Roche (Switzerland)), Yosef Landesman(Karyopharm Therapeutics (United States)), Andrea Lenzi(Canadian Obesity Network), Monica Tortoreto(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Addis(Fondazione IRCCS Istituto Nazionale dei Tumori), Michael Kauffman(Roche (Switzerland)), Andrea Mancini(Azienda Unità Sanitaria Locale Della Romagna)
Journal of Hematology & Oncology
October 5, 2014
Cited by 72


Related Papers